Long-Term Protective Immunity Induced by a GRA6-Containing Virus-like Particle Vaccine Against Toxoplasma gondii (ME49) Infection
Vaccines · 16.11.2026 · 14 (11) · 989
DOI: 10.3390/vaccines14110989 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 16.11.2026. Verfasst von Su In Heo und 5 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Dongguk University.
Abstract (Originalsprache)
Background
Virus-like particle (VLP) vaccines against Toxoplasma gondii (T. gondii) have mainly been evaluated in terms of short-term protection, with limited information available on their long-term protection. In this study, we developed a VLP vaccine displaying T. gondii dense granule protein 6 (GRA6) and evaluated its long-term protective efficacy against T. gondii ME49 challenge infection.
Methods
GRA6 VLPs were generated using a recombinant baculovirus expression system and were characterized using Western blotting and transmission electron microscopy. Mice were immunized intramuscularly three times with GRA6 VLPs and after 6 months were challenged orally with ME49. Four weeks after challenge, the mice were sacrificed and protective immunity was evaluated.
Results
GRA6 VLP immunization elicited sustained T. gondii-specific immunoglobulin G (IgG), IgG1, and IgG2a antibody responses, with the IgG2a isotype dominant. GRA6 VLP immunization induced antigen-specific IgG antibody-secreting cells in the spleen and bone marrow, and enhanced germinal center B cells, memory B cells, and memory CD4+ and CD8+ T-cell responses. GRA6 VLP immunization significantly reduced brain parasite burden and inflammatory cytokine levels (interferon-gamma and interleukin-6), while reducing body weight loss after ME49 challenge.
Conclusions
GRA6 VLP immunization conferred sustained protection even 6 months after the final immunization, as evidenced by enhanced humoral and cellular immune responses, reduced brain parasite burden, and body weight loss. These findings support the use of GRA6 VLPs as a promising non-infectious vaccine platform for inducing long-term protective immunity and limiting parasite persistence and tissue cyst formation.
Förderung
- National Research Foundation of Korea
- Dongguk University
Zitieren
APA
Heo, S. I., Kang, H., Piao, Y., Nam, H., Lee, J., & Quan, F. (2026). Long-Term Protective Immunity Induced by a GRA6-Containing Virus-like Particle Vaccine Against Toxoplasma gondii (ME49) Infection. Vaccines, 14(11), 989. https://doi.org/10.3390/vaccines14110989
Vancouver
Heo SI, Kang H, Piao Y, Nam H, Lee J, Quan F. Long-Term Protective Immunity Induced by a GRA6-Containing Virus-like Particle Vaccine Against Toxoplasma gondii (ME49) Infection. Vaccines. 2026;14(11):989. doi:10.3390/vaccines14110989
BibTeX
@article{Heo2026,
author = {Heo, Su In and Kang, Hae-Ji and Piao, Ying and Nam, Hyeon-Woo and Lee, Ji-Hyun and Quan, Fu-Shi},
title = {Long-Term Protective Immunity Induced by a GRA6-Containing Virus-like Particle Vaccine Against Toxoplasma gondii (ME49) Infection},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {11},
pages = {989},
doi = {10.3390/vaccines14110989}
}
EUVIMED